30 results about "Hormaomycin" patented technology

The invention discloses a novel peptide analogue juvenile hormone synthesis inhibitor which has a structure general formula D: R-Phe-Gly-Leu-NH2, wherein the R stands for (substituted) benzoyl, (substituted) benzene acetyl, (substituted) hydrocinnamoyl, (substituted) butylbenzene, (substituted) benzene valeryl, (substituted) benzene hexanoyl, (substituted) benzene acryloyl, diacid, fatty acid, hydrophobic amino acid, or the like. For the compound with the formula D, a tripeptide fragment Phe-Gly-Leu-NH2 of AST is used as a primer, and an N-end modification method is adopted to obtain a novel peptide analogue compound containing Phe-Gly-Leu-NH2 tripeptide which has simple structure. The activity of most compounds with the formula D is superior to that of the tripeptide fragment Phe-Gly-Leu-NH2, and the activity of an individual compound is equal to or superior than the activity of core pentapeptide of the natural AST. In the further application study, the partial compounds with the formula D have better in-vivo activity, thereby being the novel peptide analogue juvenile hormone synthesis inhibitor.

An abscisic acid (1) is a plant hormone widely existing in a plant and has important physiological function, however, the application range is limited by the high-speed photo-isomerization characteristics. A bioisosteres cis 2, 3-cyclopropanated abscisic acid analogue of the abscisic acid is compounded through 2, 3-cyclopropanation, and the photostability is four times as that of the abscisic acid.

The invention provides a method for screening a I type 17 beta-hydroxysteroid dehydrogenase inhibitor through an immobilized enzyme, and belongs to the technical field of enzymology and enzyme engineering. I type 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD1) has the important function in treating hormone-dependent diseases. At present, a substrate radiolabelling method is mainly adopted in studying the activity of 17 beta-HSD1, due to the fact that the free enzyme of 17 beta-HSD1 is likely to be inactivated, 17 beta-HSD1 is hard to prepare, a fresh placenta is needed for preparing an enzyme source in a new medicine screening experiment of every time, raw materials are hard to obtain, the price is high, and difficulty is brought to the screening work of new medicine. According to the method, an amino-modified silicon ball is adopted as a carrier, a glutaraldehyde crosslinking method is utilized, 17 beta-HSD1 extracted from the placenta is fixed, an external immobilization 17 beta-HSD1 enzyme model is built, androstenedione is adopted as a substrate, a high performance liquid chromatography method is used for detecting products, and the potential 17 beta-HSD1 inhibitor is screened. According to the method, instability of the free enzyme is overcome, operation is easy, the manufacturing cost is low, and repeated using is achieved.

The invention provides recombinant native and mutein forms of human follicle stimulating hormone beta subunit (FSH beta) with characteristic glycosylation patterns which are influential in the metabolic activity of the protein. The invention also provides recombinant mutant forms of the human alpha subunit common to FSH, LH, CG, and TSH, to obtain hormones which also have unique glycosylation patterns. Also provided are recombinant materials to produce these subunits separately or together to obtain complete heterodimeric hormones of regulated glycosylation pattern.

The invention relates to a naphthlamide derivative used as a protein kinase inhibitor and a histone deacetylase inhibitor. The structure of the naphthlamide derivative is as shown as a formula I, wherein a position 7 is provided with substituent groups R which include F, Cl, Br, I, OCH3 and other substituent groups as shown in the accompanying drawings, and the names of the substituent groups arefluorine, chlorine, bromine, iodine, methoxyl, 4-morpholinyl ethyoxyl, 4-morpholinyl methyl phenyl, acryloyl amino and 2-beuteamide. The naphthlamide derivative used as the protein kinase inhibitor and the histone deacetylase inhibitor can be used for curing cardiovascular diseases, metabolic diseases, allergy, cancers and hormone-related diseases. The invention additionally provides a synthesis method of the compound. The method has the advantages that the raw materials are easy to obtain, the method is simple to operate and the method is suitable for large-scale industrial production.

The invention provides a preparation method of natamycin produced by fermentation regulation of Streptomyces gilvosporeus and relates to the technical field of bioengineering. The method comprises steps as follows: strain activation, primary seed culture and shake flask fermentation, wherein the strain is Streptomyces gilvosporeus, ATCC 13326. The influence of three different plant hormones including IAA, GA and 6-BA, as well as precursor substance sodium propionate added in a fermentation process in a compounding manner on Streptomyces gilvosporeus cell growth and natamycin synthesis are investigated in order to understand the regulating effect of the plant hormones and the precursor substance on Streptomyces gilvosporeus cell growth and natamycin synthesis, and experimental evidence is provided for improving the efficiency of Streptomyces gilvosporeus fermentation based natamycin production by the plant hormones and the precursor substance.

The invention provides a method for synthesizing an intermediate of a 17-bit hydroxyl acylated cortical hormone steroid medicament. The intermediate compound has a structural formula shown in the specification; 17-steroid carboxylic ester has a structural formula shown in the specification; and according to the method, a 17-bit ester group protected product is obtained by reducing an acid ester open loop under the catalysis of a gluconic acid aqueous solution. By adopting the method, a hydrolysis reaction is carried out by using the recyclable gluconic acid aqueous solution for catalysis, so that the use of organic solvent and reagents is effectively reduced, the cost is reduced, pollution is reduced, and the synthesis process is simplified.

The invention relates to application of Gamma-aminobutyric acid in enhancing salt-stressed maize photosynthesis and regulating endogenous hormone and relates to application of Gamma-aminobutyric acid in maize growth and development. The invention is intended to provide novel application of Gamma-aminobutyric acid. The Gamma-aminobutyric acid can regulate salt-stressed endogenous hormone in maize seedlings. The content of endogenous GABA in salt-stressed maize leaves and roots is increased. The decrease in the content of endogenous hormone in salt-stressed maize roots is relieved. The content of gibberellin in salt-stressed leaves and roots is increased. The decrease in the content of zeatin riboside in salt-stressed maize leaves and roots is relieved. The content of abscisic acid in salt-stressed leaves and roots is decreased. The Gamma-aminobutyric acid can regulate salt-stressed maize leave photosynthetic system, thereby increasing SPAD (soil and plant analyzer development) value, photosynthetic rate, transpiration rate and stomatal conductance for maize leaves. The application is used in the field of maize cultivation.

Disclosed is a microorganism having an excellent ability to convert sterol into and rost-4-ene-3,17-dione (AD) and androsta-1,4-diene-3,17-dione (ADD), a method for preparation of the microorganism and use thereof, and more particularly, a mutant strain of Mycobacterium fortuitum ATCC 29472, Mycobacterium fortuitum EUG-119, a method for preparation of the mutant and use thereof in preparing AD and ADD. The mutant of the present invention has an excellent ability to convent sterol into AD and ADD which are steroid hormone precursors, compared with the known microorganisms and accordingly, is very useful for mass production of steroid hormones.

A cDNA clone (HEV1) encoding hevein was isolated via polymerase chain reaction (PCR) using mixed oligonucleotides corresponding to two regions of hevein as primers and a Hevea brasiliensis latex cDNA library as a template. HEV1 is 1018 nucleotides long and includes an open reading frame of 204 amino acids. The deduced amino acid sequence contains a putative signal sequence of 17 amino acid residues followed by a 187 amino acid polypeptide. The amino-terminal region (43 amino acids) is identical to hevein and shows homology to several chitin-binding proteins and to the amino-termini of wound-induced genes in potato and poplar. The carboxyl-terminal portion of the polypeptide (144 amino acids) is 74-79% homologous to the carboxyl-terminal region of wound-inducible genes of potato. Wounding, as well as application of the plant hormones abscisic acid and ethylene, resulted in accumulation of hevein transcripts in leaves, stems and latex, but not in roots, as shown by using the cDNA as a probe. A fusion protein was produced in E. coli from the protein of the present invention and maltose binding protein produced by the E. coli.

Disclosed is a microorganism having an excellent ability to convert sterol into and rost-4-ene-3,17-dione (AD) and androsta-1,4-diene-3,17-dione (ADD), a method for preparation of the microorganism and use thereof, and more particularly, a mutant strain of Mycobacterium fortuitum ATCC 29472, Mycobacterium fortuitum EUG-119, a method for preparation of the mutant and use thereof in preparing AD and ADD. The mutant of the present invention has an excellent ability to convent sterol into AD and ADD which are steroid hormone precursors, compared with the known microorganisms and accordingly, is very useful for mass production of steroid hormones.

The invention describes a retro-inverso (RI) gonadotropin-releasing hormone (GnRH) peptide which is capable of eliciting an immune response directed against GnRH, the peptide having the amino acid sequence GPRLGYSWHX, wherein the amino acids are D-amino acids and X is any amino acid. More particularly, X is E, Q, P or G, and even more particularly, X is E or Q. Thus, a preferred amino acid sequence for the peptide is GPRLGYSWHE. The peptide may optionally include one or more additional D-amino acids at its N- or C-terminus, for example a cysteine residue or a series of linker amino acids, such as a plurality of glycine amino acid residues. Thus, a second preferred amino acid sequence for the peptide is GPRLGYSWHEC, which includes a cysteine residue at the C-terminus for conjugation purposes. The invention also describes a vaccine composition for use in controlling fertility, heat, contraception and / or treating sex hormone-related diseases, and a method for controlling and or treating fertility and sex hormone-related diseases.

Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.

The inventors have discovered that substituting amino acid residues at positions 5 and / or 7 and / or 8 of the GnRH I (gonadotropin-releasing hormone) peptide sequence, and particularly removal of the arginine residue at position 8, results in elevated antiproliferative activitey. Furthermore, the introduction of certain D-amino acid residues at position 6 of the GnRH II peptide sequence results in elevated antiproliferative activity. This surprising discovery provides potent and selective agents for use in treating antiproliferative disorders, such as cancer.

The present invention relates to a monoclonal antibody for resisting swine growth hormone, its preparation method and application. It includes heavy chain variable region and light chain variable region, every variable region has respective amino acid sequence. Said invention utilizes the screening process to obtain the hybridoma strain with stable secretion swine growth hormone monoclonal antibody, and can prepare monoclonal antibody with secretion specificity for resisting swine growth hormone, so that it can lay the foundation for further creating quick, flexible and specific swine growth hormone detection method and developing new-type growth promoter.

The invention discloses a method for synthesizing an artificial antigen of progesterone, belonging to the technical field of biochemical industry. Specific hydroxyl on a progesterone analogue 17alpha-methyl-17beta-hydroxy steroid-4-alkene-3-ketone is utilized as a reaction group, and reacts with a 2-bromoacetic acid to obtain a progesterone hapten; and the hapten is connected with carrier protein bull serum albumin (BSA) to synthesize the artificial antigen of the progesterone by adopting a mixed anhydride method or the hapten is connected with carrier protein OVA to synthesize a coating antigen. The artificial antigen of the progesterone is successfully synthesized by the method; the synthesis process is simple; a plurality of parts with the same steroid hormone ring structures are fully exposed by the synthesis product; a group-selectivity progesterone monoclonal antibody can be obtained when the method is applied to immunoassay; and the national requirements of multiplex detection on progestational hormone are met.

A pharmacologic agent for treating and / or preventing cancer, among other diseases and conditions, and particularly breast, prostate, and pancreatic cancer, in humans and animals. The novel pharmacologic agent is an isoflavonoid or isoflavonoid mimetic covalently attached to a cytotoxic pharmacophore that, preferably has the ability to conjugate with a metal salt to form a more potent metal complex, particularly a Cu(II) complex. The isoflavonoid or isoflavonoid mimetic may he non-fragmented steroidal hormone, such as progesterone which is structurally related to the isoflavone genistein, or a small molecule hormone mimetic, such as chromone. An illustrative non-fragmented steroidal embodiment is 17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,13,14,15, 16,17-tetradecahydrocyclopenta[a]phenanthren-3-thiosemicarbazone and its Cu(II) complex. Effective chromone analogs include the thiosemicarbazone and hydrazone analogs of 4-oxo-4H-chromene-3-carboxaldehyde and their Cu(IT) complexes.

The present invention relates to a conjugate of the formula P-L-I, wherein P is a peptide hormone effecting the metabolism of carbohydrates in vivo, L is a hydrolysable linker molecule consisting of Lp and Li, and I is a molecule capable of inhibiting the effect of the peptide hormone P on the metabolism of carbohydrates in vivo. Under in vivo conditions, the conjugate is the major compound. When the concentration of glucose increases in vivo, the concentration of the peptide hormone effecting the metabolism of carbohydrates in vivo also increases.

Compositions and methods are described for making and using transgenic plants and plant parts having at least one auxotrophic requirement for an essential compound such as an amino acid, carbohydrate, fatty acid, nucleic acid, vitamin, plant hormone, or precursor thereof. Transgenic plants and plants parts having at least one auxotrophic requirement can be effectively biocontained by withdrawal of the essential compound.

The invention relates to a preparation method of a recombinant human corticotropin releasing factor, characterized in that: by artificially synthesizing a gene sequence of human corticotropin releasing factor mature peptide, the gene sequence is inserted into an escherichia coli expression vector with a thioredoxin label, the target gent fuses with the thioredoxin 3'end, the central part of the vector contains an associated peptide and an enterokinase recognition site, and the expression vector is converted into appropriate escherichia coli to obtain genetic engineering bacteria, the genetic engineering bacteria is subject to optimized high-density fermentation and purification to prepare Trx-CRF fusion protein, then the Trx-CRF fusion protein is subject to enterokinase cutting, and then separation and purification are carried out to obtain the recombinant human corticotropin releasing factor. The prepared recombinant human corticotropin releasing factor has the advantages of high purity, good activity, and low production cost.

The invention relates to four recombinant human corticotropin (ACTH) precursor proteins having an effect of increasing glucocorticoid levels in serum: ProACTH113, ProACTH72, ProACTH80, ProACTH141, anda method for preparing these four precursor proteins. ProACTH113 contains the 105th to 217th amino acid polypeptide chain of Pro-opiomelanocortin (POMC), ProACTH72 contains the 105th to 176th amino acid polypeptide chain of POMC, ProACTH80 contains the 138th and 217th amino acid polypeptide chains of POMC, and ProACTH141 contains the 77th to 217th amino acid polypeptide chains of POMC; all of thefour ACTH precursor proteins comprise amino acid sequences 1 to 39 of the ACTH polypeptide. For purification, the N-terminus of the four precursor proteins, ProACTH113, ProACTH72, ProACTH80, and ProACTH141, are linked to an enterokinase substrate sequence (EKst), and excess peptide sections connected with the N-terminus of the four precursor proteins are excised in vitro using histone-linked enterokinase. The free ProACTH113, ProACTH72, ProACTH80, and ProACTH141 are generated, and the histone-linked enterokinase is removed using a nickel column.

Novel Saccharomyces Cerevisiae mutant strains are provided for producing human parathyroid hormone. The novel strains acre genetically disrupted in at least one of the genes encoding the yapsin family of proteases Yapsin 1, Yapsin 2 and Yapsin 3 and harbor a human parathyroid hormone gene in their genomes. Culturing the novel strains results in the secretion of intact hPTH into culture media at high yield.

The invention relates to a compound inhalation preparation containing carbapenem antibiotic and glucocorticoid and applications thereof. The carbapenem antibiotic is made into an inhalation dosage form, so that the preparation can treat pulmonary bacterial infection with less dosage form and the happening rate of adverse reactions in the gastrointestinal tracts is prominently reduced.

The invention is directed toward a human glycoprotein hormone having at least one, two, three, four, or five basic amino acids in the α-subunit at positions selected from the group consisting of positions 11, 13, 14, 16, 17, and 20. The invention is also directed to a human glycoprotein where at least one of the amino acids at position 58, 63, and 69 of the β-subunit of the human thyroid stimulating hormone are basic amino acids. The invention is further directed to a modified human glycoprotein hormone having increased activity over a wild-type human glycoprotein hormone, where the modified human glycoprotein comprises a basic amino acid substituted at a position corresponding to the same amino acid position in a non-human glycoprotein hormone having an increased activity over the wild-type human glycoprotein hormone. The invention is also directed to a method of constructing superactive nonchimeric analogs of human hormones comprising comparing the amino acid sequence of a more active homolog from another species to the human hormone, and selecting superactive analogs from the substituted human hormones. The invention is also directed to nucleic acids encoding the modified human glycoprotein hormones, vectors containing those nucleic acids, and host cells containing those vectors.

The invention belongs to the technical field of microorganisms, and discloses an application of ensifer meliloti CGMCC7333 in biotransformation of 3-indole acetonitrile to generate 3-indoleacetamide. The bacterial strain disclosed by the invention is easy to cultivate, and has the characteristics of simple process, high conversion ratio and the like when being applied to biological catalysis of the 3-indole acetonitrile to synthesize the 3-indoleacetamide. The product 3-indoleacetamide can be used as a medical intermediate and applied to synthesis of phytohormone 3-heteroauxin and the like.